Construction and anti-tumor effects of recombinant fowlpox virus expressing Newcastle disease virus hemagglutinin-neuramidinase gene

Chinese Science Bulletin

Volumn 51, Issue 22, 2006, Pages 2724-2730

  Li, Xiao ^a,b   Jin, Ningyi ^a   Lian, Hai ^a   Guan, Goufang ^c   Sun, Lili ^c   Li, Xuemei ^a   Zheng, Hongling ^a  

^a BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^b JILIN UNIVERSITY   (China)

^c Basic Medical College   (China)

Author keywords

Anti tumor; Fowlpox virus vector; HN gene; NDV

Indexed keywords

FOWLPOX VIRUS; MAMMALIA; NEWCASTLE DISEASE VIRUS;

EID: 33751273165     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-006-2176-z     Document Type: Article

References (26)

1. Dziadek S, Espinola C G, Kunz H. Synthetic glycopeptides for the development of antitumor vaccines. Aust J Chem, 2003, 56: 519-543
2. Haas C, Lulei M, Fournier P, et al. A tumor vaccine containing anti-CD3 and anti-CD28 bispecific antibodies triggers strong and durable antitumor activity in human lymphocytes. Intl J Cancer, 2006, 118(3): 658-667
3. Mebatsion T, Koolen M J M, de Vaan L T C, et al. Newcastle Disease Virus (NDV) marker vaccine: An immunodominant epitope on the nucleoprotein gene of NDV can be deleted or replaced by a foreign epitope. J Virol, 2002, 76(20): 10138-10146
4. Schirrmacher V, Haas C, Bonifer R, et al. Human tumor cell modification by virus infection: An efficient and safe way to produce cancer vaccine with pleiotropic immune stimulatory properties when using Newcastle disease virus. Gene Ther, 1999, 6: 63-73
5. Bian H, Fournier P, Moormann R, et al. Selective gene transfer to tumor cells by recombinant Newcastle Disease Virus via a bispecific fusion protein. Intl J Oncol, 2005, 26: 431-439
6. Bian H, Fournier P, Moormann R, et al. Selective gene transfer in vitro to tumor cells via recombinant Newcastle disease virus. Cancer Gene Ther, 2005, 12: 295-303
7. Schirrmacher V. Clinical trials of antitumor vaccination with an autologous tumor cell vaccine modified by virus infection: Improvement of patient survival based on improved antitumor immune memory. Cancer Immunol Immuneother, 2005, 54: 587-598
8. Zeng J, Fournier P, Schirrmacher V. Induction of interferon-α and tumor necrosis factor-related apoptosis-inducing ligand in human blood mononuclear cells by Hemagglutinin-Neuraminidase but not F protein of Newcastle Disease Virus. Virology, 2002, 297: 19-30
9. Li X, Jin N Y, Mi Z Q, et al. The construction of nucleic vaccine expressing apoptin gene, Newcastle disease virus HN gene and IL-18 gene and its antitumor effect on B16. High Technol Lett (in Chinese), 2004, 14(12): 33-36
10. Jin N Y, Zhang H Y, Zheng M, et al. Immunogenicity of recombinant fowl-pox virus co-expressing structural protein precursor P1-2A and proteinase 3C of FMDV. Chin Sci Bull (in Chinese), 2004, 49(8): 823-827
11. Jiang W Z, Jin N Y, Cui S F, et al. Construction and characterization of recombinant fowlpox virus coexpressing HIV-1CN gp120 and IL-2. J Virol Methods, 2005, 130(1-2): 95-101
12. Ribble D, Goldstein N B, Norris D A, et al. A simple technique for quantifying apoptosis in 96-well plates. BMC Biotechnol, 2005, 5: 12
13. Cao X J, Wang Y M. Serum sialic acid detection with 3,5-dihydroxytoluene. J Clin Test (in Chinese), 1998, 16(3): 153-154
14. Slavin-Chiorini D C, Catalfamo M, Kudo-Saito C, et al. Amplification of the lytic potential of effector/memory CD8+ cells by vector-based enhancement of ICAM-1 (CD54) in target cells: Implications for intratumoral vaccine therapy. Cancer Gene Ther, 2004, 11: 665-680
15. Pharoah P D, Dunning A M, Ponder B A, et al. Association studies for finding cancer-susceptibility genetic variants. Cancer, 2004, 11(4): 850-860
16. Haviv Y S, Curiel D T. Conditional gene targeting for cancer gene therapy. Adv Drug Deliv Rev, 2001, 53: 135-154
17. El-Aneed A. Current strategies in cancer gene therapy. Eur J Pharmacol, 2004, 498: 1-8
18. Cassel W A, Garret R E. Newcastle disease virus as an antineoplastic agent. Cancer, 1965, 7: 863-868
19. Connaris H, Takimoto T, Russell R, et al. Probing the sialic acid binding site of the hemagglutinin-neuraminidase of Newcastle Disease Virus: Identification of key amino acids involved in cell binding, catalysis, and fusion. J Virol, 2002, 76(4): 1816-1824
20. Iorio R M, Field G M, Sauvron J M, et al. Sauvron,et al. Structural and functional relationship between the receptor recognition and neuraminidase activities of the Newcastle Disease Virus hemagglutinin-neuraminidase protein: Receptor recognition is dependent on neuraminidase activity. J Virol, 2001, 75(4): 1918-1927
21. McGinnes L W, Gravel K, Morrison, T G. Newcastle Disease Virus HN protein alters the conformation of the F protein at cell surfaces. J Virol, 2002, 76(24): 12622-12633
22. Washburn B, Weigand M A, Grosse-Wilde A, et al. TNF-related apoptosis-inducing ligand mediates tumoricidal activity of human monocytes stimulated by Newcastle Disease Virus. J Immunol, 2003, 170: 1814-1821
23. Mahnke Y D, Schirrmacher V. A novel tumor model system for the study of long-term protective immunity and immune T cell memory. Cell Immunol, 2003, 221: 89-99
24. Washburn B, Schirrmacher V. Human tumor cell infection by Newcastle disease virus leads to upregulation of HLA and cell adhesion molecules and to induction of interferons, chemokines and finally apoptosis. Intl J Oncol, 2002, 21: 85-93
25. Webster D P, Dunachie S, McConkey S, et al. Safety of recombinant fowlpox strain FP9 and modified vaccinia virus Ankara vaccines against liver-stage P. falciparum malaria in non-immune volunteers. Vaccine, 2006, 24: 3026-3034
26. Marshall J L, Gulley J L, Arlen P M, et al. Phase I study of sequential vaccinations with fowlpox-CEA(6D)-TRICOM alone and sequentially with vaccinia-CEA(6D)-TRICOM, with and without granulocyte-macrophage colony-stimulating factor, in patients with carcinoembryonic antigen-expressing carcinomas. J Clin Oncol, 2005, 23: 720-731